Exabis Library
Welcome to the e-CCO Library!
P573 Frequency and effectiveness of empirical anti-TNF dose intensification in inflammatory bowel disease: an on-going systematic review with meta-analysis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P573: Change in fatigue in patients with Ulcerative Colitis or Crohn's disease initiating vedolizumab or other biologic therapy: Data from Belgian registry patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P573: Comparative effectiveness of second-line biological therapies for Ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P573: Impact of the duration of combination therapy on clinical and pharmacological efficacy of infliximab in inflammatory bowel diseases
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P573: Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P573: Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteers
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P573: The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P574 Incidence and indicators of suboptimal response to tumour necrosis factor antagonist therapy in Chinese patients with inflammatory bowel disease: Results from the EXPLORE study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P574: Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P574: Exploring treatment of Crohn’s disease and ulcerative colitis in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P574: IBD patients should be stratified to guide out-of-hospital monitoring: ICHOM-derived outcomes from a dedicated IBD telephone clinic
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P574: Limitations and difficulties in using anti-TNF-alpha agents in inflammatory bowel disease. A survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P574: Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn‘s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P574: The effects of vagus nerve stimulation in biologic-refractory Crohn’s disease: A prospective clinical trial
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P575 Real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn’s disease: The Scottish ustekinumab cohort
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P575: AZA-related toxicity isn't aggravated by concomitant drugs in IBD patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P575: Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P575: Nutrition and Inflammatory Bowel Disease – a nationwide survey of patients, gastroenterologists and dietitians
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P575: Safety and efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease after cyclophosphamide-free mobilisation: Preliminary Results
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P575: Simple novel tacrolimus enemas are very effective in severe refractory proctitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM